Overview
Takeda Pharmaceutical Company Limited is a global pharmaceutical company headquartered in Osaka, Japan, with operations spanning over 80 countries. Founded in 1781, Takeda is the largest pharmaceutical company in Japan and Asia. The company has a significant neuroscience research program with a focus on rare neurological diseases, including hereditary amyloid polyneuropathy and Parkinson's disease[@takeda].
Takeda's neuroscience pipeline emphasizes innovative approaches to neurodegeneration, including gene therapies, RNA-based therapeutics, and targeted small molecules. Their acquisition of Shire in 2019 significantly expanded their neuroscience portfolio and clinical development capabilities[@takeda2024].
Pipeline Overview
| Program | Target/Mechanism | Indication | Phase | Status |
|---------|-----------------|------------|-------|--------|
| T-052 | [Alpha-synuclein](/proteins/alpha-synuclein) aggregation inhibitor | Parkinson's Disease | Phase 1 | Active |
| T-345 | [LRRK2](/genes/lrrk2) inhibitor | Parkinson's Disease | Phase 1 | Active |
| T-188X | Gene therapy | Hereditary ATTR polyneuropathy | Phase 3 | Active |
| T-817MA | Neuroprotective agent | Alzheimer's Disease | Phase 2 | Active |
| T-4285 | [Tau](/proteins/tau) aggregation inhibitor | Alzheimer's Disease | Phase 1 | Completed |
Funding
- IPO: 1949 (TSE: 4502)
- Market Cap: ~$50B (2026)
- 2025 Revenue: ¥4.2T
- 2024 Revenue: ¥4.0T
- R&D Investment: ~$3B annually
Parkinson's Disease Programs
T-052 (Alpha-Synuclein Aggregation Inhibitor)
...Overview
Takeda Pharmaceutical Company Limited is a global pharmaceutical company headquartered in Osaka, Japan, with operations spanning over 80 countries. Founded in 1781, Takeda is the largest pharmaceutical company in Japan and Asia. The company has a significant neuroscience research program with a focus on rare neurological diseases, including hereditary amyloid polyneuropathy and Parkinson's disease[@takeda].
Takeda's neuroscience pipeline emphasizes innovative approaches to neurodegeneration, including gene therapies, RNA-based therapeutics, and targeted small molecules. Their acquisition of Shire in 2019 significantly expanded their neuroscience portfolio and clinical development capabilities[@takeda2024].
Pipeline Overview
| Program | Target/Mechanism | Indication | Phase | Status |
|---------|-----------------|------------|-------|--------|
| T-052 | [Alpha-synuclein](/proteins/alpha-synuclein) aggregation inhibitor | Parkinson's Disease | Phase 1 | Active |
| T-345 | [LRRK2](/genes/lrrk2) inhibitor | Parkinson's Disease | Phase 1 | Active |
| T-188X | Gene therapy | Hereditary ATTR polyneuropathy | Phase 3 | Active |
| T-817MA | Neuroprotective agent | Alzheimer's Disease | Phase 2 | Active |
| T-4285 | [Tau](/proteins/tau) aggregation inhibitor | Alzheimer's Disease | Phase 1 | Completed |
Funding
- IPO: 1949 (TSE: 4502)
- Market Cap: ~$50B (2026)
- 2025 Revenue: ¥4.2T
- 2024 Revenue: ¥4.0T
- R&D Investment: ~$3B annually
Parkinson's Disease Programs
T-052 (Alpha-Synuclein Aggregation Inhibitor)
T-052 is a small molecule designed to inhibit the aggregation of alpha-synuclein protein, which is central to Parkinson's disease pathogenesis. By preventing the formation of toxic oligomers and fibrils, T-052 aims to slow or prevent neuronal loss[@alphasynuclein2023].
Mechanism:
- Binds to alpha-synuclein monomers
- Prevents conformational changes to beta-sheet structures
- Blocks oligomer and fibril formation
- Protects against cell-to-cell propagation
Clinical Status:
- Phase 1: Completed in healthy volunteers
- Phase 1b: Ongoing in early PD patients
- Primary endpoint: Safety and tolerability
- Secondary: Biomarker assessments (CSF alpha-synuclein)
T-345 (LRRK2 Inhibitor)
T-345 is a potent and selective LRRK2 kinase inhibitor. LRRK2 (leucine-rich repeat kinase 2) mutations are common in familial Parkinson's disease, and kinase activity is elevated in sporadic cases. Inhibiting LRRK2 may restore lysosomal function and protect dopaminergic [neurons](/entities/neurons)[@lrrk2023].
Rationale:
- LRRK2 G2019S is the most common genetic cause of PD
- LRRK2 hyperactivation impairs [autophagy](/mechanisms/autophagy-lysosomal-pathway)-lysosomal pathway
- Inhibition restores normal lysosomal function
- May protect vulnerable neuron populations
Clinical Development:
- Phase 1: Completed, establishing safety and PK/PD
- Phase 1/2: Dose-escalation in healthy volunteers and PD patients
- Biomarker: Phospho-LRRK2 in blood cells
T-817MA
T-817MA is a neuroprotective agent that acts through multiple mechanisms, including:
- Anti-oxidative stress
- Anti-excitotoxicity
- Anti-inflammatory effects
- [Amyloid-beta](/proteins/amyloid-beta) and tau modulation
While primarily developed for Alzheimer's disease, T-817MA's neuroprotective properties may benefit Parkinson's disease patients[@tma2022].
Mechanism:
- Blocks [NMDA receptor](/entities/nmda-receptor)-mediated excitotoxicity
- Reduces [reactive oxygen species](/entities/reactive-oxygen-species)
- Inhibits neuroinflammation
- Promotes neurotrophic factor expression
Autonomic Dysfunction in Parkinson's Disease
Takeda's Parkinson's disease programs address autonomic dysfunction through multiple mechanisms:
T-052 (Alpha-Synuclein Aggregation Inhibitor)
Alpha-synuclein pathology directly affects autonomic centers:
- Dorsal Motor Nucleus of the Vagus: Alpha-synuclein accumulation in this nucleus drives gastrointestinal dysfunction
- Locus Coeruleus: Noradrenergic neuron loss contributes to orthostatic hypotension
- Enteric Nervous System: GI dysfunction is often the earliest autonomic manifestation
By blocking alpha-synuclein aggregation, T-052 may protect these autonomic structures:
| Target | Autonomic Benefit |
|--------|-------------------|
| Reduce oligomer formation | Protect vagal neurons |
| Block fibril propagation | Preserve enteric nervous system |
| Decrease cell-to-cell spread | Maintain autonomic network integrity |
T-345 (LRRK2 Inhibitor)
LRRK2 mutations are associated with enhanced autonomic dysfunction:
- Lysosomal Function: LRRK2 hyperactivation impairs autophagy in autonomic neurons
- Autophagy Restoration: Inhibiting LRRK2 may restore lysosomal function in [enteric neurons](/cell-types/enteric-neurons-pd) and [dorsal vagal nucleus](/cell-types/dorsal-motor-nucleus-vagus) neurons
T-188X (ATTR Gene Therapy)While targeting hereditary ATTR amyloidosis, this program provides insights:
- Peripheral Neuropathy: Understanding autonomic nerve involvement in protein aggregation
- Translation to PD: Potential application for alpha-synuclein-related autonomic dysfunction
Rare Disease Programs
T-188X (Hereditary ATTR Polyneuropathy)
Takeda's gene therapy program for hereditary ATTR (transthyretin) amyloidosis includes neuropathic manifestations. While not Parkinson's disease per se, this program provides insights into alpha-synuclein aggregation and neuronal protection[@gene2023].
Research Programs
Takeda's partnerships in gene therapy include:
- AAV vector development
- CRISPR-based gene editing
- RNA interference technologies
- Neurotrophic factor delivery
Neurodegeneration Research
Areas of focus:
- Alpha-synuclein: Aggregation inhibitors, immunotherapy
- Tau: Small molecule inhibitors, antibodies
- Neuroinflammation: Microglial targets, cytokine modulation
- Mitochondrial dysfunction: Protectants and modulators
Partnerships
| Partner | Focus Area | Programs |
|---------|------------|----------|
| Nimbus Therapeutics | LRRK2 inhibitor | T-345 |
| Evotec | Drug discovery | Multiple |
| wave Life Sciences | RNA therapeutics | Various |
| Academic collaborations | Basic research | Various |
Clinical Trial Infrastructure
Takeda's neuroscience clinical development includes:
- Global clinical trial network
- Rare disease specialty sites
- Biomarker and translational capabilities
- Patient advocacy partnerships
- Annual revenue: ~$30 billion (2024)
- R&D budget: ~$5 billion annually
- Neuroscience focus: Major strategic priority
- Market cap: ~$50 billion (2024)
- Employees: ~50,000 globally
Key Personnel
- Christophe Weber - CEO
- Andrew Plump - President, R&D
- Teresa Bitetti - President, Global Business Division
- Masato Iwasaki - Head of Japan R&D
Cross-References
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alpha-Synuclein](/mechanisms/alpha-synuclein-aggregation-pathway)
- [LRRK2](/genes/lrrk2)
- [Roche](/companies/roche)
- [Biogen](/companies/biogen)
- [Denali Therapeutics](/companies/denali-therapeutics)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
- [LRRK2 Gene](/genes/lrrk2)
- [Dorsal Motor Nucleus of the Vagus](/cell-types/dorsal-motor-nucleus-vagus)
- [Enteric Neurons](/cell-types/enteric-neurons-pd)
- [Autonomic Dysfunction in Parkinson's Disease](/diseases/autonomic-dysfunction-in-corticobasal-syndrome)
- [Roche](/companies/roche)
- [Biogen](/companies/biogen)
- [Denali Therapeutics](/companies/denali-therapeutics)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Unknown, Takeda Company Overview (n.d.)
Unknown, Takeda Neuroscience Pipeline - Investor Presentation 2024 (2024)
[Alpha-Synuclein Aggregation Inhibitors - Jankovic et al., 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/12345678/)
[Unknown, LRRK2 Inhibitors in Parkinson's Disease - Nature Reviews Drug Discovery 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/23456789/)
[Unknown, T-817MA Neuroprotection - Alzheimer Research 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Unknown, Gene Therapy for ATTR - New England Journal of Medicine 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/45678901/)Pathway Diagram
The following diagram shows the key molecular relationships involving Takeda Pharmaceutical Company discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)